Sidney Scott Devins, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 290 Ne Tudor Rd, Metropolitan Pulmonary And Hospital M, Lees Summit, MO 64086 Phone: 816-524-5522 Fax: 816-524-4798 |
Steven Glen Hull, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3470 Ne Ralph Powell Rd, Suite B, Lees Summit, MO 64064 Phone: 913-498-3003 Fax: 913-341-5958 |
Amelia Fitzpatrick, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 290 Ne Tudor Rd, Lees Summit, MO 64086 Phone: 816-524-5522 Fax: 816-524-4798 |
John Calvin Ireland, D.O. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2000 Se Blue Pkwy, Suite 270 B, Lees Summit, MO 64063 Phone: 816-333-1919 Fax: 816-333-2614 |
Rebecca Ann Ferguson, D.O. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 290 Ne Tudor Rd, Lees Summit, MO 64086 Phone: 816-524-5522 Fax: 816-524-4798 |
Dr. Eric D Friskel, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3470 Ne Ralph Powell Rd, Suite B, Lees Summit, MO 64064 Phone: 913-498-3003 Fax: 913-341-5958 |
News Archive
According to a study by a team at UC Davis Department of Public Health Sciences, everyday exposure to naturally occurring asbestos, increases the risk of developing malignant mesothelioma.
A Johns Hopkins University School of Medicine study of insurance coverage of more than 28,000 people with HIV concludes that a decades-old program that offers free medical care remains a critical necessity despite the availability of coverage under the Affordable Care Act (ACA).
Anyone who has tried and failed to meditate knows that our minds are rarely still. But where do they roam? New research led by UC Berkeley has come up with a way to track the flow of our internal thought processes and signal whether our minds are focused, fixated or wandering.
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ERĀ® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.
› Verified 3 days ago